DarioHealth (DRIO) Stock Overview
Operates as a digital health company in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
DRIO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
DarioHealth Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.20 |
| 52 Week High | US$17.74 |
| 52 Week Low | US$5.84 |
| Beta | 1.12 |
| 1 Month Change | -3.87% |
| 3 Month Change | 20.20% |
| 1 Year Change | -7.46% |
| 3 Year Change | -88.87% |
| 5 Year Change | -97.48% |
| Change since IPO | -99.90% |
Recent News & Updates
Analysis Article • Aug 17
Some Analysts Just Cut Their DarioHealth Corp. (NASDAQ:DRIO) Estimates
The latest analyst coverage could presage a bad day for DarioHealth Corp. ( NASDAQ:DRIO ), with the analysts making...Analysis Article • Aug 14
Analysts Have Made A Financial Statement On DarioHealth Corp.'s (NASDAQ:DRIO) Second-Quarter Report
Shareholders might have noticed that DarioHealth Corp. ( NASDAQ:DRIO ) filed its second-quarter result this time last...Recent updates
Analysis Article • Aug 17
Some Analysts Just Cut Their DarioHealth Corp. (NASDAQ:DRIO) Estimates
The latest analyst coverage could presage a bad day for DarioHealth Corp. ( NASDAQ:DRIO ), with the analysts making...Analysis Article • Aug 14
Analysts Have Made A Financial Statement On DarioHealth Corp.'s (NASDAQ:DRIO) Second-Quarter Report
Shareholders might have noticed that DarioHealth Corp. ( NASDAQ:DRIO ) filed its second-quarter result this time last...
Narrative Update • Jul 28
DRIO: AI Platform And 2026 Contracts Will Support Recovery
Analysts have trimmed their fair value estimate for DarioHealth from $18.80 to $15.25 per share, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E that together point to a more balanced risk and return profile for the stock. What's in the News for DarioHealth DarioHealth filed a follow-on equity offering of about US$23.6m, including 2,451,490 common shares at US$6.80 and 1,017,499 pre-funded warrants at US$6.7999 per warrant, in a registered direct structure.
Narrative Update • Jun 26
DRIO: Clinical Outcomes And Expanded Partnerships Will Drive Future Share Rebound
Analysts have maintained their $28.00 price target on DarioHealth, citing updated assumptions around the discount rate, revenue growth, profit margin and future P/E that collectively leave their valuation framework broadly unchanged. What’s in the News for DarioHealth DarioHealth presented four studies at the American Diabetes Association Scientific Sessions highlighting clinical and economic outcomes from its cardiometabolic platform across high-risk populations, with data drawn from 27 studies presented at the ADA over 8 years.Narrative Update • Jun 11
DRIO: Peer Reviewed Outcomes And GLP 1 Tools Will Drive Future Rebound
Analysts have reduced their price target on DarioHealth by $6 to $28, citing updated assumptions around revenue growth, profit margins, discount rates and future P/E as the main factors behind the revision. What's in the News DarioHealth presented four studies at the American Diabetes Association Scientific Sessions, covering high risk cardiometabolic populations and reinforcing its focus on claims based and outcomes driven payments.
Narrative Update • May 28
DRIO: Future Clinical Evidence And GLP 1 Demand Will Support Upside
Analysts have reduced their price target on DarioHealth from $16 to $10, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E in their models. Analyst Commentary Bearish analysts have adjusted their models on DarioHealth to reflect the lower US$10 price target, pointing to a mix of valuation questions and execution risks.Narrative Update • May 09
DRIO: Future Digital Health Research And GLP-1 Platform Adoption Will Drive Upside
Analysts have reduced their DarioHealth price target by $2 to $10, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts have flagged the recent cut in the DarioHealth price target to $10 as part of a broader reset in expectations around valuation and execution risk.Narrative Update • Apr 22
DRIO: Peer Reviewed Outcomes And GLP 1 Tools Will Support Future Rebound
Analysts reduced their DarioHealth price target by $6 to reflect updated assumptions on discount rates, long-term revenue growth, profit margins and future P/E levels, while keeping the estimated fair value unchanged at $28.00. Analyst Commentary Recent research points to a more tempered view of DarioHealth's risk and return profile, with price targets adjusted to reflect updated assumptions on discount rates, long term growth, margins and future P/E levels.Narrative Update • Apr 07
DRIO: Rising Digital Engagement And GLP 1 Adoption Will Support 2026 Rebound
Analysts now set a $28.00 fair value for DarioHealth, up from $25.00. This reflects updated assumptions on revenue growth, profitability, and longer term P/E levels discussed in recent research.Narrative Update • Mar 24
DRIO: AI Health Platform And Governance Changes Will Support 2026 Recovery
Analysts now set an $18.80 price target for DarioHealth, up from $18.00, citing updated assumptions on revenue growth, profit margins, and future P/E that reflect the latest Street research, including commentary from Stifel. Analyst Commentary Recent Street research includes a report titled “DarioHealth price target lowered by $6 at Stifel, here's why,” which feeds into the updated $18.80 target.Narrative Update • Mar 08
DRIO: Growing GLP-1 Digital Demand And AI Platform Will Drive 2026 Rebound
Analysts are maintaining their $25.00 price target on DarioHealth, citing only small adjustments to assumptions, including a slightly higher discount rate, a modest change to projected revenue growth, lower profit margin expectations, and a higher future P/E multiple. What's in the News DarioHealth reports increasing employer and health plan demand for its oral GLP-1 digital health solution, which is designed to support medication impact with precision behavioral tools such as adherence tracking, grocery scanning and access to human coaching (Key Developments).Narrative Update • Feb 21
DRIO: AI-Driven Hypertension Platform And Governance Updates Will Support 2026 Recovery
Analysts have modestly adjusted their price target on DarioHealth from $18.25 to $18.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Shareholders approved an amended and restated Certificate of Incorporation at the January 29, 2026 AGM, updating the company’s core governing document (Key Developments).Narrative Update • Feb 06
DRIO: 2026 Pipeline Execution Will Drive Rebound From Current Weakness
Analysts have lifted their price target for DarioHealth to US$11 from US$0.60, pointing to updated models that balance recent revenue softness with expectations that the current pipeline could start to matter more from 2026 onward. Analyst Commentary Bullish analysts are pointing to the reset price target of US$11, up from US$0.60, as a sign that their updated models are assigning more value to DarioHealth's longer term potential, even while near term revenue remains soft.Analysis Article • Feb 06
DarioHealth Corp.'s (NASDAQ:DRIO) 27% Share Price Plunge Could Signal Some Risk
DarioHealth Corp. ( NASDAQ:DRIO ) shares have had a horrible month, losing 27% after a relatively good period...Narrative Update • Jan 23
DRIO: Pipeline Execution In 2026 Will Drive The Investment Case
Analysts cut their fair value estimate for DarioHealth from $80.00 to $25.00, pointing to softer revenue growth assumptions, lower long term profit margins, and a higher future P/E multiple aligned with recent Street research that factors in current revenue weakness along with a potential recovery supported by the company's pipeline. Analyst Commentary Bullish analysts point to the recent price target reset as a sign that expectations are now more closely aligned with the company’s current revenue trends, while still assigning value to the potential in its pipeline.Narrative Update • Jan 08
DRIO: Pipeline And AI Platform Are Expected To Drive 2026 Recovery
Narrative Update on DarioHealth Analysts lifted their price target on DarioHealth to US$11 from US$0.60, citing updated models that factor in ongoing revenue weakness alongside a strong pipeline that they believe could support a potential recovery in 2026. Analyst Commentary Recent research gives a mixed read on DarioHealth, with the higher price target to US$11 sitting alongside caution around current business trends.Analysis Article • Dec 23
Does DarioHealth (NASDAQ:DRIO) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Dec 15
DRIO: Recovery Is Expected To Resume In 2026 On Pipeline Execution
Analysts have modestly increased their price target on DarioHealth to $11.00 from $0.60, citing updated models that balance ongoing revenue weakness with expectations that the company’s strong pipeline could drive a recovery in 2026. Analyst Commentary Analysts are digesting the latest quarterly results and recalibrating their expectations for DarioHealth, with valuation shifts reflecting both the pressure from current fundamentals and the potential upside tied to the company’s longer term growth pipeline.Narrative Update • Nov 30
DRIO: Recovery Should Accelerate in 2026 as Pipeline Matures
Analysts have lowered their price target for DarioHealth from $19.75 to $18.25. They cited continued revenue weakness, while also anticipating potential recovery driven by a strong pipeline.Narrative Update • Nov 16
DRIO: Strong Pipeline Will Drive Meaningful Recovery by 2026
Analysts have lowered their price target for DarioHealth from $22.25 to $19.75, citing concerns about slower revenue growth and a weaker profit margin. Some anticipate potential recovery if the company's strong pipeline delivers in coming years.Narrative Update • Nov 01
DRIO: New Client Wins And Pricing Initiatives Will Drive Upside Potential
Analysts have reiterated their target price for DarioHealth at $22.25 per share. They are maintaining their outlook based on updated assumptions regarding discount rates and profit margins.Narrative Update • Oct 17
Integrated Digital Health And AI Will Expand Chronic Care Markets
Narrative Update: DarioHealth Analysts have maintained their price target for DarioHealth at $22.25, citing stable growth projections and recent adjustments to key financial metrics. What's in the News DarioHealth announced the addition of six new employer clients, expanding its value-based care strategy by implementing a pricing model tied to member engagement and clinical outcomes (Client Announcements).Narrative Update • Oct 03
Integrated Digital Health And AI Will Expand Chronic Care Markets
DarioHealth's analyst price target has been revised downward from $25.50 to $22.25. This reflects analysts' updated outlook based on lower fair value estimates and a slightly reduced discount rate.Analysis Article • Sep 21
DarioHealth Corp. (NASDAQ:DRIO) Stock's 42% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, DarioHealth Corp. ( NASDAQ:DRIO ) shares are down a considerable 42% in the last...Narrative Update • Sep 16
Integrated Digital Health And AI Will Expand Chronic Care Markets
DarioHealth’s fair value estimate has been reduced, driven by a substantial drop in future P/E and a higher discount rate, resulting in the analyst price target falling from $39.25 to $25.50. What's in the News Launched five new contracts with self-insured employers for Dario’s full cardiometabolic suite, demonstrating improvements in diabetes (1.4% eHbA1c reduction), prediabetes (10% BMI reduction), and hypertension (38% users lowered stage).Narrative Update • Aug 29
Integrated Digital Health And AI Will Expand Chronic Care Markets
DarioHealth’s fair value assessment has increased markedly due to a substantial drop in future P/E, outweighing a minor rise in the discount rate, resulting in the consensus analyst price target jumping from $1.96 to $39.25. What's in the News DarioHealth announced a 1-for-20 reverse stock split to be implemented as determined by the Board no later than September 15, 2025.Analysis Article • Aug 15
Downgrade: Here's How Analysts See DarioHealth Corp. (NASDAQ:DRIO) Performing In The Near Term
The latest analyst coverage could presage a bad day for DarioHealth Corp. ( NASDAQ:DRIO ), with the analysts making...Narrative Update • Aug 15
Integrated Digital Health And AI Will Expand Chronic Care Markets
With both the discount rate and revenue growth forecasts holding steady, analyst valuation for DarioHealth remained unchanged, with the consensus price target steady at $1.96. What's in the News Shareholders ratified the appointment of Kesselman & Kesselman (PwC) as independent auditor for 2025.Analysis Article • Aug 01
DarioHealth Corp. (NASDAQ:DRIO) Doing What It Can To Lift Shares
DarioHealth Corp.'s ( NASDAQ:DRIO ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a buy right now...Analysis Article • Apr 17
DarioHealth Corp. (NASDAQ:DRIO) Screens Well But There Might Be A Catch
DarioHealth Corp.'s ( NASDAQ:DRIO ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a buy right now...
New Narrative • Apr 15
Twill Integration And GLP-1 Focus Will Expand Health Solutions
DarioHealth is positioned for significant revenue growth through strategic integrations, rising demand for companion solutions, and expanding market reach via partnerships.Analysis Article • Nov 17
Slammed 25% DarioHealth Corp. (NASDAQ:DRIO) Screens Well Here But There Might Be A Catch
DarioHealth Corp. ( NASDAQ:DRIO ) shares have had a horrible month, losing 25% after a relatively good period...Analysis Article • Oct 03
A Piece Of The Puzzle Missing From DarioHealth Corp.'s (NASDAQ:DRIO) 27% Share Price Climb
Those holding DarioHealth Corp. ( NASDAQ:DRIO ) shares would be relieved that the share price has rebounded 27% in the...Shareholder Returns
| DRIO | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 1.6% | -0.1% | -0.1% |
| 1Y | -7.5% | -18.1% | 11.9% |
Return vs Industry: DRIO exceeded the US Healthcare Services industry which returned -17.7% over the past year.
Return vs Market: DRIO underperformed the US Market which returned 12.1% over the past year.
Price Volatility
| DRIO volatility | |
|---|---|
| DRIO Average Weekly Movement | 10.4% |
| Healthcare Services Industry Average Movement | 10.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: DRIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DRIO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 163 | Erez Raphael | www.dariohealth.com |
DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a behavioral health offering that decreases the symptoms of stress, anxiety, and depression; Dario Move, focuses on improving posture to alleviate pain with medical device; and Dario Health, a self-care application and virtual coaching platform for diabetes, hypertension, and weight management and GLP-1.
DarioHealth Corp. Fundamentals Summary
| DRIO fundamental statistics | |
|---|---|
| Market cap | US$70.56m |
| Earnings (TTM) | -US$7.00m |
| Revenue (TTM) | US$21.00m |
3.4x
P/S Ratio-10.1x
P/E RatioIs DRIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRIO income statement (TTM) | |
|---|---|
| Revenue | US$21.00m |
| Cost of Revenue | US$8.07m |
| Gross Profit | US$12.93m |
| Other Expenses | US$19.93m |
| Earnings | -US$7.00m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 61.57% |
| Net Profit Margin | -33.33% |
| Debt/Equity Ratio | 56.4% |
How did DRIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 03:32 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DarioHealth Corp. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| null null | CG Capital |
| David Grossman | Stifel, Equities Research |